Review Articles

PI3K inhibitors in chronic lymphocytic leukemia: where do we go from here?

Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway; K. G. Jebsen Centre for B Cell Malignancies, Institute of Clinical Medicine, University of Oslo, Oslo
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA
Haematologica Early view Jul 28, 2022 https://doi.org/10.3324/haematol.2022.281266